TITLE

Research Highlights

AUTHOR(S)
M. B.; E. C.; C. S.; J. B.; J. C. L.; A. F.
PUB. DATE
August 2006
SOURCE
Nature Medicine;Aug2006, Vol. 12 Issue 8, p892
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article summarizes medical research findings. These include a study showing the beneficial effects of the beta blocker bucindolol in a subgroup of individuals carrying a specific polymorphism in the drug's target, two studies outlining a mechanism for neuron death in Down syndrome, and two studies examining the role of circadian proteins in aging and drug metabolism.
ACCESSION #
21856960

 

Related Articles

  • Do beta blockers cut Alzheimer's risk? NEWMAN, ELIZABETH // McKnight's Assisted Living;Feb2013, Vol. 11 Issue 1, p4 

    The article reports on the Honolulu-Asia Aging Study, which found that men with hypertension and had been treated with beta blockers has fewer brain lesions associated with Alzheimer's disease.

  • When not to use beta-blockers in seniors with hypertension. Schumann, Sarah-Anne; Hickner, John // Journal of Family Practice;Jan2008, Vol. 57 Issue 1, p18 

    The article discusses updates on the use of beta-blockers for hypertension treatment in elderly. Two systematic reviews of beta-blockers trials are said to have helped overturn a long-held belief about the value of beta-blockers for the treatment of hypertension. They did raise the concern about...

  • Continuous Monitoring of Circadian Variations in Intraocular Pressure by Telemetry System Throughout a 12-Week Treatment with Timolol Maleate in Rabbits. Akaishi, Takahiro; Ishida, Naruhiro; Shimazaki, Atsushi; Hara, Hideaki; Kuwayama, Yasuaki // Journal of Ocular Pharmacology & Therapeutics;Dec2005, Vol. 21 Issue 6, p436 

    Aim: The aim of this study was to examine the effect of a 12-week treatment with two formulations of timolol maleate on the amplitude of the circadian fluctuation in intraocular pressure (IOP). Methods: Conscious Japanese White rabbits housed under a controlled 12-hour light-dark cycle were...

  • Behavioral disturbance and treatment strategies in Smith-Magenis syndrome. Poisson, Alice; Nicolas, Alain; Cochat, Pierre; Sanlaville, Damien; Rigard, Caroline; de Leersnyder, Hélène; Franco, Patricia; Des Portes, Vincent; Edery, Patrick; Demily, Caroline // Orphanet Journal of Rare Diseases;9/6/2015, Vol. 10 Issue 1, p1 

    Background: Smith-Magenis syndrome is a complex neurodevelopmental disorder that includes intellectual deficiency, speech delay, behavioral disturbance and typical sleep disorders. Ninety percent of the cases are due to a 17p11.2 deletion encompassing the RAI1 gene; other cases are linked to...

  • Treatment of raised intraocular pressure and prevention of glaucoma. Wormald, R // BMJ: British Medical Journal (International Edition);4/5/2003, Vol. 326 Issue 7392, p723 

    Discusses the treatment of raised intraocular pressure and the prevention of glaucoma. Reference to a study published in the 'Archives of Opthamology' in 2002; Ethical questions surrounding the offering of lowering pressure as a treatment for glaucoma; Ocular hypertension treatment study...

  • Heart rate target treatment shortfall in contemporary beta-blocker therapy of heart failure in 446 patients in sinus rhythm. Scalia, G.; Scalia, I.; Scalia, W.; Rafter, L.; Rafter, T.; Cross, D. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS207 

    No abstract available.

  • Should Patients with COPD Exacerbations Receive Beta Blockers? Pierson, David J. // Internal Medicine Alert;8/15/2008, Vol. 30 Issue 15, p113 

    The findings of this retrospective study of 825 patients hospitalized with COPD exacerbations indicate that the use of beta blockers in such patients is not harmful and may actually be associated with reduced mortality.

  • Should patients at lower cardiac risk receive beta-blockers before noncardiac surgery?  // JAAPA: Journal of the American Academy of Physician Assistants (;Mar2010, Vol. 23 Issue 3, p53 

    The article discusses the use of beta-blockers before a noncardiac surgery. Beta-blockers functions as a very good example of how medical practice is influenced by the understanding and interpretation of the evidence-based media and the clinicians. Studies have been proposed that the use of...

  • Eligible patients may miss out on early β-blocker therapy.  // PharmacoEconomics & Outcomes News;2/24/2007, Issue 522, p7 

    The article discusses research being done on the patterns of use and potential impact of early β-blocker therapy in non-ST-segment elevation myocardial infarction (NSTEMI). It references a study by M. Emery et al published in the December 2006 issue of the "American Heart Journal." Findings...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics